APA (7th ed.) Citation

Kawczak, P., Kawczak, K., & Bączek, T. (2026). Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin. Journal of Clinical Medicine, 15(13), 4886. https://doi.org/10.3390/jcm15134886

Chicago Style (17th ed.) Citation

Kawczak, Piotr, Katarzyna Kawczak, and Tomasz Bączek. "Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin." Journal of Clinical Medicine 15, no. 13 (2026): 4886. https://doi.org/10.3390/jcm15134886.

MLA (9th ed.) Citation

Kawczak, Piotr, et al. "Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin." Journal of Clinical Medicine, vol. 15, no. 13, 2026, p. 4886, https://doi.org/10.3390/jcm15134886.